Yamogenin
Based on 1 Customer Validation
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes. Yamogenin is a steroidal saponin that can be obtained from plant species with in vitro cytotoxicity, antioxidant, and antimicrobial properties. Yamogenin induces cell death via the extrinsic and intrinsic way of apoptosis. Yamogenin inhibits protein denaturation with an IC50 of 1421.92 μg/mL. Yamogenin can be studied in research on gastric cancer.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 512-06-1
- Formula: C27H42O3
- Molecular Weight:414.62
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
IC50: TG accumulation; liver X receptor (LXR)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>20 μg/mL
Compound: 10
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 23511021] |
| Hep 3B2 | IC50 |
>20 μg/mL
Compound: 10
|
Cytotoxicity against human Hep3B cells
Cytotoxicity against human Hep3B cells
|
[PMID: 23511021] |
| HepG2 | IC50 |
>20 μg/mL
Compound: 10
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 23511021] |
| MCF7 | IC50 |
>20 μg/mL
Compound: 10
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 23511021] |
| MDA-MB-231 | IC50 |
>20 μg/mL
Compound: 10
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 23511021] |
Yamogenin (5-60 µg/mL, 24 h) decreases the viability of AGS cells with an IC50 of 18.5 µg/mL[2].
Yamogenin (10-60 µg/mL, 24 h) increases the amount of apoptotic and dead AGS cells[2].
Yamogenin (10-60 µg/mL, 48 h) induces cell cycle arrest in subG1 phase in AGS cells[2].
Yamogenin (30-100 µg/mL,5-24 h) triggers activation of caspase-8 and -9 in AGS cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AGS cells
-
Concentration:10, 30, 60 µg/mL
-
Incubation Time:24 h
-
Result:Significanlty decreased the mitochondrial membrane potential with high concentrations.
Significantly induced oxidative stress at higher used concentrations.
Chemical Information
-
CAS No. 512-06-1
-
Appearance Solid
-
Molecular Weight 414.62
-
Formula C27H42O3
-
Color White to light yellow
-
SMILES
O[C@]1([H])CC2=CC[C@]3([H])[C@@](CC[C@@]4(C)[C@@]3([H])C[C@@]5([H])[C@]4([H])[C@@](C)([H])[C@@]6(CC[C@]([H])(C)CO6)O5)([H])[C@@]2(C)CC1
-
Synonyms
Neodiosgenin
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
Ethanol : 8.33 mg/mL (20.09 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Moriwaki S, et al. Yamogenin in fenugreek inhibits lipid accumulation through the suppression of gene expression in fatty acid synthesis in hepatocytes.Biosci Biotechnol Biochem. 2014;78(7):1231-6. [Content Brief]
[2]. Stefanowicz-Hajduk, J., et al., (2024). An In Vitro Study on the Cytotoxic, Antioxidant, and Antimicrobial Properties of Yamogenin-A Plant Steroidal Saponin and Evaluation of Its Mechanism of Action in Gastric Cancer Cells. International journal of molecular sciences, 25(9), 4627. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.4118 mL | 12.0592 mL | 24.1185 mL | 60.2962 mL |
| 5 mM | 0.4824 mL | 2.4118 mL | 4.8237 mL | 12.0592 mL | |
| 10 mM | 0.2412 mL | 1.2059 mL | 2.4118 mL | 6.0296 mL | |
| 15 mM | 0.1608 mL | 0.8039 mL | 1.6079 mL | 4.0197 mL | |
| 20 mM | 0.1206 mL | 0.6030 mL | 1.2059 mL | 3.0148 mL |